Double or Triple Trouble in Metastatic Hormone-sensitive Prostate Cancer?

The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) has rapidly evolved over the past decade. Multiple landmark phase 3 randomised clinical trials (RCTs) have shown a significant overall survival (OS) benefit with the use of doublet therapy combining androgen deprivation therapy (ADT) with either docetaxel chemotherapy or novel hormonal therapies (NHTs). On this basis, a doublet regimen is now recognised as the standard of care for mHSPC. Attention has now turned to the potential role of triplet therapy in mHSPC, that is, ADT + docetaxel + NHT.